Biohaven Ltd. Debt Securities, Available-for-sale, Amortized Cost
Biohaven Ltd. (BHVN) had Debt Securities, Available-for-sale, Amortized Cost of $134.41 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Credit Losses › Credit Loss, Additional Improvements
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $134.41M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $150.53M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $114.11M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $75.34M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $134.41M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $150.53M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $114.11M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $75.34M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $308.94M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $224.29M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $386.79M 10-K · filed 2026-03-02 |
| 2024-03-31 | $108.74M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $167.32M 10-K · filed 2025-03-03 |
| 2023-09-30 | $133.98M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $187.76M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $273.27M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $310.50M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |